A grand jury indicted Automated Medical Laboratories, Inc. (AML), Richmond Plasma Corporation (RPC) (a wholly owned AML subsidiary), and three former RPC managers for engaging in a conspiracy that included falsification of logbooks and records required to be maintained by businesses producing blood plasma. The falsification was designed to conceal from the Food and Drug Administration (FDA) various violations of federal regulations governing the plasmapheresis process and facilities. The evidence introduced at trial indicated that the managers and several other members of the team charged with ensuring compliance with FDA regulations had actively participated in record falsification. AML was convicted and appealed on the ground that there was no evidence that any officer or director of AML knowingly or willfully participated in or authorized the unlawful practices at RPC. Was AML’s conviction in the absence of such proof proper?